- Published articles
- Congress presentations
-
The novel uncompetitive NMDA receptor antagonist esmethadone has no meaningful abuse potential in recreational drug users
-
REL-1017 (esmethadone) as adjunctive treatment in patients with major depressive disorder: a phase 2 randomized double-blind trial
-
Subanalysis of subjective cognitive measures from a phase 2, double-blind, randomized trial of REL-1017 in patients with major depressive disorder
-
Esmethadone‐HCl (REL‐1017): a promising rapid antidepressant
-
Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial
-
No Indication of Abuse Potential and Absence of Withdrawal Signs and Symptoms From Esmethadone (REL-1017): Results From a Phase 3 Randomized Controlled Trial in Patients With Major Depressive Disorder
-
Esmethadone (REL-1017) compares with NMDA receptor antagonists in FLIPR-calcium assay
-
REL-1017 (esmethadone hydrochloride), a potential rapid-acting antidepressant has no meaningful opioid abuse potential in non-clinical and clinical abuse potential studies
-
REL-1017 (esmethadone) may rapidly reduce dissociative symptoms in adults with major depressive disorder unresponsive to standard antidepressants: a report of 2 cases
-
No meaningful abuse potential in recreational ketamine users of REL-1017 (esmethadone hydrochloride), a new NMDAR antagonist and potential rapid-acting antidepressant
-
REL-1017 (esmethadone hydrochloride) demonstrates neither toxic effects on maternal health nor teratogenic effects in pregnant rats
-
REL-1017 (esmethadone) increases circulating BDNF levels in healthy subjects of a phase 1 clinical study
-
Characterization of the safety and pharmacokinetic profile of d-methadone, a novel N-methyl-D-aspartate receptor antagonist in healthy, opioid-naive subjects: results of two phase 1 studies
-
No meaningful abuse potential in recreational opioid users of REL-1017 (esmethadone hydrochloride), a new NMDAR antagonist and potential rapid-acting antidepressant
-
Pharmacological comparative characterization of REL-1017 (esmethadone-HC1) and other NMDAR channel blockers in human heterodimeric N-Methyl-D-Aspartate receptors
-
The N-Methyl-D-Aspartate receptor blocker REL-1017 (esmethadone) reduces calcium influx induced by glutamate, quinolinic acid and gentamicin
-
REL-1017 (esmethadone hydrochloride) a novel uncompetitive NMDAR antagonist with a preference for NR1-NR2D subtypes shows rapid, robust and sustained rapid antidepressant effects as adjunctive treatment for Major Depressive Disorder
-
No meaningful opioid abuse liability of REL-1017 (esmethadone; d-methadone), a rapid-acting antidepressant in clinical development: a human abuse potential study
-
REL-1017 (esmethadone, D-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats
-
REL-1017 (esmethadone), a novel NMDAR blocker for the treatment of MDD is not neurotoxic in Sprague-Dawley rats
-
Esmethadone (REL-1017) blocks NMDA receptors and reduces Ca2+ entry in presence of quinolinic acid and gentamicin
-
REL-1017 (esmethadone) showed no reinforcing properties compared to oxycodone in a rat self-administration study
-
The N-methyl-D-aspartate receptor antagonist d-methadone acutely improves depressive-like behavior in the forced swim test performance of rats
-
N-methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects
-
REL-1017 (esmethadone) demonstrates no physical dependence and no withdrawal effects in a rat study
-
No meaningful abuse potential in recreational opioid users of REL-1017 (esmethadone hydrochloride), a new NMDAR antagonist and potential rapid-acting antidepressant
-
No meaningful abuse potential in recreational ketamine users of REL-1017 (esmethadone hydrochloride), a new NMDAR antagonist and potential rapid-acting antidepressant
-
Case report: REL-1017 reduces abnormal Clinician Administered Dissociative States Scale scores in patients with major depressive disorder
-
A Phase 2a double-blind randomized trial of REL-1017 (esmethadone) in patients with major depressive disorder: Analysis of subscales from the Symptoms of Depression Questionnaire
-
Effect of REL-1017 (esmethadone) on cholesterol, triglycerides, PCSK9 and hs-CRP in patients with major depressive disorder
-
Effect of percentage of life-years from the start of major depressive disorder on the therapeutic response to REL-1017
-
Esmethadone (REL-1017) reduces glutamate-induced currents in NMDA receptors with the GluN2D subunit
-
Esmethadone (REL-1017) reduces NMDA receptor currents in a concentration dependent manner
-
Esmethadone (REL-1017) shows slower onset kinetics compared to ketamine in manual patch clamp studies
-
Esmethadone (REL-1017) restores NMDA receptor 1 subunit expression in an in vitro model of glutamatergic excitotoxicity
-
Esmethadone (REL-1017) and other uncompetitive NMDAR channel blockers may improve mood disorders via modulation of synaptic kinase-mediated signaling
Published articles
The novel uncompetitive NMDA receptor antagonist esmethadone has no meaningful abuse potential in recreational drug users
Transl Psychiatry 13, 192 (2023)
Published articles
REL-1017 (esmethadone) as adjunctive treatment in patients with major depressive disorder: a phase 2 randomized double-blind trial
Am J Psychiatry. 2022 Feb;179(2):122-131.
Published articles
Subanalysis of subjective cognitive measures from a phase 2, double-blind, randomized trial of REL-1017 in patients with major depressive disorder
Prim Care Companion CNS Disord. 2023;25(1):22m03267.
Published articles
Esmethadone‐HCl (REL‐1017): a promising rapid antidepressant
Eur Arch Psychiatry Clin Neurosci. 2023.
Congress presentations
Efficacy and Safety of Esmethadone (REL-1017) in Patients With Major Depressive Disorder and Inadequate Response to Standard Antidepressants: A Phase 3 Randomized Controlled Trial
American Society of Clinical Psychopharmacology (ASCP) 2023
Congress presentations
No Indication of Abuse Potential and Absence of Withdrawal Signs and Symptoms From Esmethadone (REL-1017): Results From a Phase 3 Randomized Controlled Trial in Patients With Major Depressive Disorder
American Society of Clinical Psychopharmacology (ASCP) 2023
Congress presentations
Esmethadone (REL-1017) compares with NMDA receptor antagonists in FLIPR-calcium assay
Society of Biological Psychiatry (SOBP) Annual Meeting 2021.
Biological Psychiatry. 2021;89(9), S294.
Congress presentations
REL-1017 (esmethadone hydrochloride), a potential rapid-acting antidepressant has no meaningful opioid abuse potential in non-clinical and clinical abuse potential studies
The College of Problems of Drug Dependence (CPDD) 2022.
Published articles
REL-1017 (esmethadone) may rapidly reduce dissociative symptoms in adults with major depressive disorder unresponsive to standard antidepressants: a report of 2 cases
Journal of Clinical Psychopharmacology. 2022;10.1097/JCP.0000000000001583.
Congress presentations
No meaningful abuse potential in recreational ketamine users of REL-1017 (esmethadone hydrochloride), a new NMDAR antagonist and potential rapid-acting antidepressant
American Society of Clinical Psychopharmacology (ASCP) 2022.
Congress presentations
REL-1017 (esmethadone hydrochloride) demonstrates neither toxic effects on maternal health nor teratogenic effects in pregnant rats
Society of Biological Psychiatry (SOBP) Annual Meeting 2022.
Published articles
REL-1017 (esmethadone) increases circulating BDNF levels in healthy subjects of a phase 1 clinical study
Frontiers in Pharmacology. 2021;12:973-978.
Published articles
Characterization of the safety and pharmacokinetic profile of d-methadone, a novel N-methyl-D-aspartate receptor antagonist in healthy, opioid-naive subjects: results of two phase 1 studies
Journal of Clinical Psychopharmacology. 2019;39(3):226-237.
Congress presentations
No meaningful abuse potential in recreational opioid users of REL-1017 (esmethadone hydrochloride), a new NMDAR antagonist and potential rapid-acting antidepressant
Ketamine 2022.
Published articles
Pharmacological comparative characterization of REL-1017 (esmethadone-HC1) and other NMDAR channel blockers in human heterodimeric N-Methyl-D-Aspartate receptors
Pharmaceuticals 2022;15(8):997.
Published articles
The N-Methyl-D-Aspartate receptor blocker REL-1017 (esmethadone) reduces calcium influx induced by glutamate, quinolinic acid and gentamicin
Pharmaceuticals. 2022;15 (7), 882.
Congress presentations
REL-1017 (esmethadone hydrochloride) a novel uncompetitive NMDAR antagonist with a preference for NR1-NR2D subtypes shows rapid, robust and sustained rapid antidepressant effects as adjunctive treatment for Major Depressive Disorder
Ketamine 2022.
Congress presentations
No meaningful opioid abuse liability of REL-1017 (esmethadone; d-methadone), a rapid-acting antidepressant in clinical development: a human abuse potential study
American College of Neuropsychopharmacology (ACNP) 60th Annual Meeting 2021.
Neuropsychopharmacol. 46, 218-368, P315 (2021).
Published articles
REL-1017 (esmethadone, D-methadone) does not cause reinforcing effect, physical dependence and withdrawal signs in Sprague Dawley rats
Scientific Reports. 2022;12,11389.
Published articles
REL-1017 (esmethadone), a novel NMDAR blocker for the treatment of MDD is not neurotoxic in Sprague-Dawley rats
Frontiers in Pharmacology. 2022. 13:863959.
Congress presentations
Esmethadone (REL-1017) blocks NMDA receptors and reduces Ca2+ entry in presence of quinolinic acid and gentamicin
Society of Biological Psychiatry (SOBP) Annual Meeting 2021.
Biological Psychiatry. 2021;89(9), S198.
Congress presentations
REL-1017 (esmethadone) showed no reinforcing properties compared to oxycodone in a rat self-administration study
The College on Problems of Drug Dependence (CPDD) Annual Meeting 2021.
Published articles
The N-methyl-D-aspartate receptor antagonist d-methadone acutely improves depressive-like behavior in the forced swim test performance of rats
Exp Clin Psychopharmacol. 2020;28(2):196-201.
Published articles
N-methyl-D-aspartate receptor antagonist d-methadone produces rapid, mTORC1-dependent antidepressant effects
Neuropsychopharmacology. 2019;44(13):2230-2238.
Congress presentations
REL-1017 (esmethadone) demonstrates no physical dependence and no withdrawal effects in a rat study
The College on Problems of Drug Dependence (CPDD) Annual Meeting 2021.
Congress presentations
No meaningful abuse potential in recreational opioid users of REL-1017 (esmethadone hydrochloride), a new NMDAR antagonist and potential rapid-acting antidepressant
American Society of Clinical Psychopharmacology (ASCP) 2022.
Congress presentations
No meaningful abuse potential in recreational ketamine users of REL-1017 (esmethadone hydrochloride), a new NMDAR antagonist and potential rapid-acting antidepressant
Ketamine 2022.
Congress presentations
Case report: REL-1017 reduces abnormal Clinician Administered Dissociative States Scale scores in patients with major depressive disorder
Neuroscience Education Institute (NEI) 2021.
CNS Spectrums, Volume 27, Issue 2, April 2022, pp. 236.
Congress presentations
A Phase 2a double-blind randomized trial of REL-1017 (esmethadone) in patients with major depressive disorder: Analysis of subscales from the Symptoms of Depression Questionnaire
Neuroscience Education Institute (NEI) 2021.
CNS Spectrums, Volume 27, Issue 2, April 2022, pp. 235.
Congress presentations
Effect of REL-1017 (esmethadone) on cholesterol, triglycerides, PCSK9 and hs-CRP in patients with major depressive disorder
Neuroscience Education Institute (NEI) 2021.
CNS Spectrums, Volume 27, Issue 2, April 2022, pp. 246 – 247.
Congress presentations
Effect of percentage of life-years from the start of major depressive disorder on the therapeutic response to REL-1017
American Psychiatric Association (APA) Annual Meeting 2021.
Congress presentations
Esmethadone (REL-1017) reduces glutamate-induced currents in NMDA receptors with the GluN2D subunit
Society of Biological Psychiatry (SOBP) Annual Meeting 2021.
Biological Psychiatry. 2021;89(9), S198-S199.
Congress presentations
Esmethadone (REL-1017) reduces NMDA receptor currents in a concentration dependent manner
Society of Biological Psychiatry (SOBP) Annual Meeting 2021.
Congress presentations
Esmethadone (REL-1017) shows slower onset kinetics compared to ketamine in manual patch clamp studies
Society of Biological Psychiatry (SOBP) Annual Meeting 2021.
Biological Psychiatry. 2021;89(9), S294-S295.
Congress presentations
Esmethadone (REL-1017) restores NMDA receptor 1 subunit expression in an in vitro model of glutamatergic excitotoxicity
Society of Biological Psychiatry (SOBP) Annual Meeting 2021.
Biological Psychiatry. 2021;89(9), S383-S384.
Published articles
Esmethadone (REL-1017) and other uncompetitive NMDAR channel blockers may improve mood disorders via modulation of synaptic kinase-mediated signaling
Int. J. Mol. Sci. 2022; 23(20), 12196.
You are leaving Relmada.com
By clicking YES, you will be directed to another website. Click NO to remain on this page. Do you wish to continue to another website?